ArticleJTCVS techniques2026
Anomalous left vertebral artery in patients undergoing total arch replacement: Results from a prospective trial.
Article in JTCVS techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Anomalous left vertebral artery (ALVA) originating from the aorta presents a challenge when performing total arch replacement. This has been addressed with in situ stent grafting using the hybrid branched stented anastomosis frozen elephant repair (B-SAFER) technique and studied as part of a prospective, physician-sponsored investigational device exemption trial. We describe management and outcomes in patients with ALVA undergoing B-SAFER. Methods: A total of 15 of 420 (4%) patients who underwent B-SAFER from May 2021 to February 2025 had ALVA. Average age was 63 ± 10 years, and 12 (80%) were male. Indications were acute dissection 7 (47%), chronic dissection 4 (27%), and degenerative aneurysm 4 (27%). No patients had a previous stroke, 3 (20%) had a history of transient ischemic attack (TIA), 4 (27%) had carotid artery disease, and 4 (27%) had a history of atrial fibrillation. Average circulatory arrest time was 55 ± 28 minutes. Average follow-up time was 525 ± 374 days. Results: ALVA was stent grafted in 13 (87%) patients and ligated/covered in 2 (13%) patients. Average ALVA diameter was 5.4 ± 1.7 mm in stented and 3.3 ± 0.4 mm in nonstented patients. One patient died from cardiac arrest on postoperative day 26 after hospital discharge. There were no acute strokes, TIAs, or spinal cord ischemia events. In late follow-up, 1 TIA occurred, and there were no strokes. Paraparesis occurred in 1 patient after thoracic endovascular aortic repair 5 months postoperatively. All ALVA stents were patent on follow-up computed tomography angiography. Mean modified Rankin scale score was 1.4 ± 1.2 after discharge and 0.9 ± 1.3 on most recent follow-up. Conclusions: Stent grafting of a prominent anomalous left vertebral artery during total arch replacement using the B-SAFER technique appears feasible and safe in selected patients and is durable at intermediate follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.